Legal & General Group Plc Buys New Stake in Teladoc Health, Inc. $TDOC

Key Points

• Legal & General Group Plc acquired 160,095 Teladoc Health shares worth approximately $1.36 million in the second quarter, while institutional investors collectively own 76.82% of the company.
• Teladoc’s latest quarterly results beat EPS expectations, reporting a loss of $0.21 per share versus the anticipated $0.25 loss, but revenue declined 4% year over year to $606.93 million and remained below estimates.
• Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $7.54; TDOC recently opened at $6.29 and remains unprofitable.

Legal & General Group Plc purchased a new position in Teladoc Health, Inc. (NYSE:TDOC - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 160,095 shares of the health services provider's stock, valued at approximately $1,358,000. Legal & General Group Plc owned about 0.09% of Teladoc Health as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of TDOC. Monaco Asset Management SAM purchased a new stake in shares of Teladoc Health during the 2nd quarter valued at about $26,864,000. Jupiter Asset Management Ltd. grew its position in Teladoc Health by 293.9% in the fourth quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider's stock worth $27,021,000 after acquiring an additional 2,880,008 shares in the last quarter. Quantinno Capital Management LP grew its position in Teladoc Health by 128.0% in the first quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider's stock worth $14,287,000 after acquiring an additional 1,471,631 shares in the last quarter. Pale Fire Capital SE increased its stake in Teladoc Health by 74.8% during the first quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider's stock worth $18,522,000 after acquiring an additional 1,454,288 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Teladoc Health by 23.8% during the third quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider's stock valued at $53,260,000 after purchasing an additional 1,325,106 shares during the period. Hedge funds and other institutional investors own 76.82% of the company's stock.

Teladoc Health Trading Up 0.2%

NYSE:TDOC opened at $6.29 on Monday. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -6.35 and a beta of 2.12. Teladoc Health, Inc. has a twelve month low of $4.40 and a twelve month high of $9.89. The stock has a fifty day simple moving average of $7.79 and a 200-day simple moving average of $6.71.

Teladoc Health (NYSE:TDOC - Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The health services provider reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.04. The firm had revenue of $606.93 million for the quarter, compared to analysts' expectations of $615.44 million. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The business's revenue for the quarter was down 4.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.19) earnings per share. Teladoc Health has set its Q3 2026 guidance at -0.300--0.200 EPS and its FY 2026 guidance at -1.000--0.750 EPS. As a group, equities research analysts predict that Teladoc Health, Inc. will post -0.89 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TDOC has been the subject of a number of recent research reports. Bank of America lifted their target price on Teladoc Health from $9.00 to $10.50 and gave the stock a "buy" rating in a report on Tuesday, July 7th. Canaccord Genuity Group lowered their target price on shares of Teladoc Health from $11.00 to $10.00 and set a "buy" rating for the company in a report on Thursday, July 30th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Teladoc Health in a report on Wednesday, August 19th. Finally, Citigroup reduced their price objective on shares of Teladoc Health from $11.00 to $7.50 and set a "neutral" rating on the stock in a research report on Monday, August 3rd. Five investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Teladoc Health currently has a consensus rating of "Hold" and an average target price of $7.54.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc's service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.